Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...
Bristol Myers price target raised to $65 from $62 at Truist
Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
(Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers ...
kalkinemedia21h
How Bristol-Myers Squibb Manages Debt with Strong Earnings (NYSE:BMY)
Highlights,Bristol-Myers Squibb manages its debt effectively with solid earnings.,A substantial cash reserve supports the ...